Session Information

  • WCLC 2022

    2022 World Conference on Lung Cancer

    As an IASLC member, you can enjoy complimentary access to the presentations from the World Conference on Lung Cancer 2022. If you participated in the conference, kindly utilize the code "WCLC2022ACCESSFULL" to enter the virtual meeting and access the recordings.

    Presentation Date(s):  
    • August 6 - 9, 2022
    • Total Presentations: 2015

    All times listed are in Vienna, Austria Time, CEST (UTC+2:00)

    PL - Plenary
    IBS - Interactive Breakfast Session (in-person attendees only)
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    P - Posters
    EP - ePosters
    WS - Workshops
    LA – Lectureship Awards
    IS - Industry Symposium

Filter Results:

Show Only CME Accredited Sessions

  • +

    EP08.01 - Metastatic Non-small Cell Lung Cancer - Immunotherapy

    • 09:45 - 18:00
    • 8/07/2022
    • Location: Exhibit Hall - Hall B
    • Not for CME Credit
    • Type: E-Poster
    • Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
    • +

      EP08.01-030 - Nivolumab+Ipilimumab Vs Platinum-Based CT+Nivolumab In Advanced Lung Squamous-Cell Carcinoma: The Randomized SQUINT Trial

      Presenter: Federico Cappuzzo

      • Abstract

      Loading...

  • +

    EP08.02 - Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

    • 09:45 - 18:00
    • 8/07/2022
    • Location: Exhibit Hall - Hall B
    • Not for CME Credit
    • Type: E-Poster
    • Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
    • +

      EP08.02-048 - Crizotinib in ROS1+NSCLC: Long-term OS Analysis in Patients with Brain Metastases Included in the Phase II METROS Trial

      Presenter: Federico Cappuzzo

      • Abstract

      Loading...

  • +

    P2.14 - Tumor Biology and Biomarkers - Molecular Profiling and Targeted Therapeutics

    • 17:15 - 19:15
    • 8/08/2022
    • Location: Exhibit Hall - Hall B
    • Not for CME Credit
    • Type: Regular Poster
    • Track: Tumor Biology and Biomarkers - Molecular Profiling and Targeted Therapeutics
    • +

      P2.14-02 - TP53 Mutations Affect Sensitivity to Lorlatinib in ROS1 Positive NSCLC: Final Results of the PFROST Trial

      Presenter: Lorenza Landi

      • Abstract

      Loading...

  • +

    MA13 - Update on ROS1 Inhibitors and New Pathways

    • 12:00 - 13:00
    • 8/09/2022
    • Location: Hall C7
    • Not for CME Credit
    • Type: Mini Oral
    • Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
    • +

      Session Moderator

      12:52 - 13:00  |  Presenter: Lorenza Landi

      • Abstract

      Loading...

    • +

      Session Moderator

      12:52 - 13:00  |  Presenter: Jii Bum (Joy) Lee

      • Abstract

      Loading...

    • +

      MA13.01 - Session Introduction

      12:00 - 12:01  |  Presenter: Lorenza Landi

      • Abstract

      Loading...

    • +

      MA13.02 - Session Introduction

      12:01 - 12:02  |  Presenter: Jii Bum (Joy) Lee

      • Abstract

      Loading...

    • +

      MA13.03 - Integrated Efficacy and Safety of Brigatinib Following Alectinib Treatment in the ALTA-2 and J-ALTA Studies

      12:02 - 12:07  |  Presenter: Sai-Hong Ignatius Ou

      • Abstract

      Loading...

    • +

      MA13.04 - Entrectinib in Patients with ROS1 Fusion-Positive (ROS1-fp) NSCLC: Updated Efficacy and Safety Analysis

      12:07 - 12:12  |  Presenter: Yun Fan

      • Abstract

      Loading...

    • +

      MA13.05 - TA0953/HM06, a Novel RET-specific Inhibitor Effective in Extracranial and CNS Disease Models of NSCLC with RETfusions

      12:12 - 12:17  |  Presenter: Igor Odintsov

      • Abstract

      Loading...

    • +

      MA13.06 - Discussant

      12:17 - 12:27  |  Presenter: Lorenza Landi

      • Abstract

      Loading...

    • +

      MA13.07 - TROPION-Lung02: Initial Results for Datopotamab Deruxtecan Plus Pembrolizumab and Platinum Chemotherapy in Advanced NSCLC

      12:27 - 12:32  |  Presenter: Benjamin Levy

      • Abstract

      Loading...

    • +

      MA13.08 - A Phase 1 Trial of Sapanisertib and Telaglenastat (CB-839) in Patients With Advanced NSCLC (NCI 10327): Results from Dose Escalation

      12:32 - 12:37  |  Presenter: Jonathan Riess

      • Abstract

      Loading...

    • +

      MA13.09 - Time from Immune Checkpoint Inhibitor to Sotorasib Use Correlates with Risk of Hepatotoxicity in Non-small Cell Lung Cancer

      12:37 - 12:42  |  Presenter: Sagar Rakshit

      • Abstract

      Loading...

    • +

      MA13.10 - Discussant

      12:42 - 12:52  |  Presenter: Paolo Bironzo

      • Abstract

      Loading...

    • +

      MA13.11 - Live Q&A

      12:52 - 13:00

      • Abstract

      Loading...